Saline Versus Nafamostat Mesilate Anticoagulation for Continuous Veno-venous Hemofiltration (CVVH) in Patients at High Risk of Bleeding: A Prospective Study / 대한신장학회지
Korean Journal of Nephrology
;
: 205-210, 2009.
Article
in Korean
| WPRIM
| ID: wpr-38231
ABSTRACT
PURPOSE:
In patients with a higherrisk of bleeding, performing CVVH with heparin or saline anticoagulation is associated with increased bleeding or thrombotic risk. Nafamostat mesilate (NM), a serine proteinase inhibitor, while inhibiting various clotting factors in filter circuit, is characterized by short half life resulting in little systemic anticoagulation effect. Accordingly, we prospectively evaluated the anticoagulant effect and safety of NM in patients with a higher risk of bleeding who underwent CVVH.METHODS:
Among 43 patients with high risk of bleeding [defined by (1) INR>2, aPTT>20 sec, platelet2, aPTT>20 sec, platelet<50,000/mm3), the positive effect of NM on circuit lifespan persisted irrespective of the coagulation status.CONCLUSION:
As compared with saline bolus, nafamostat mesilate infusion was associated with higher CVVH filter life. In patients with high risk of bleeding, nafamostat mesilate can be used as a safe and effective anticoagulant for CVVH with acceptable filter life
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Heparin
/
Prospective Studies
/
Hemofiltration
/
Mesylates
/
Serine Proteases
/
Guanidines
/
Half-Life
/
Hemorrhage
Type of study:
Etiology study
/
Observational study
Limits:
Humans
Language:
Korean
Journal:
Korean Journal of Nephrology
Year:
2009
Type:
Article
Similar
MEDLINE
...
LILACS
LIS